Novocure Phase 3 TRIDENT trial fails to show survival benefit for early TTFields in GBM

NovoCure Ltd

• Median OS 17.7 mo (Early Start) vs 17.5 mo (Maintenance Start); HR 0.953, p=0.519.
• 981 patients enrolled; 25% did not initiate maintenance phase across both arms.
• 1-/2-/3-year survival rates: Early Start 70.9%/33.9%/22.5%; Maintenance 72.0%/31.6%/18.4%.
• No new safety signals; TTFields with chemoradiation was well-tolerated.
• Results accepted for presentation at ASTRO 2026 Annual Meeting.